STAT3 and cancer: This study not only provides a novel metal-Cp*-based STAT3 inhibitor chemoimmunotherapeutic agents for treating colon cancer, but also further highlights the efficacy of the metal–ligand synergetic enhancement strategy in cancer treatment.